FIGURE 1.
mIGFL is produced as a soluble dimeric protein and is up-regulated in inflammatory skin conditions in mice. A, Coomassie-stained PAGE gels of purified FLAG-mIGFL (left) and FLAG-IGFL1 (right) run under reducing (Red.) or non-reducing (NR) conditions. B, serum from mice injected with FLAG-mIGFL or control vector was assayed for mIGFL by ELISA at 6 and 24 h post-injection (n = 5, ±S.E.). No signal was detect (ND) for control vector pRK. C, RT-PCR analysis of mIGFL expression in normal mouse tissue is shown. mIGFL copy numbers were determined by comparing sample Ct values to Ct values generated with a dilution series of a known copy number of mIGFL cDNA, then normalized to the average mIGFL expression levels (±S.D.). D, clinical scores (left) and ear thickness (right) in the Imiquimod-induced psoriasis model in mice were monitored every other day during the treatment regimen. E, mIGFL expression, normalized to expression levels of RPL19, in skin RNA of mice treated daily for 5 days with Imiquimod (n = 5 treated and n = 3 untreated, ±S.E.) is shown. F, microarray analysis of mIGFL expression on day 7 after a full thickness skin punch (n = 5, ±S.E.) is shown. UT, untreated.